Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.6
Journals
IJMS
Special Issues
Recent Advances in Omics for Cancer Research
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Recent Advances in Omics for Cancer Research

A Special Issue of International Journal of Molecular Sciences (ISSN 1422-0067) belonging to the section "Molecular Oncology".

Deadline for manuscript submissions: 30 September 2026 | Viewed by 1168

Editor

Prof. Dr. Hassan Ghazal

E-Mail Website
Guest Editor
1. Laboratory of Precision Medicine and One Health (MedPreOne), Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca 82403, Morocco
2. Royal Institute of Executive Management for Youth and Sport (IRFC), Department of Sports Sciences, Laboratory of Sports Sciences and Performance Optimization, Salé 10102, Morocco
Interests: genomics; microbiome; diabetes; cancer genetics

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue entitled Recent Advances in Omics for Cancer Research, which focuses on the expanding role of omics technologies in deciphering the molecular complexity of cancer.

Cancer is a multifactorial and heterogeneous disease driven by genetic, epigenetic, metabolic and microenvironmental alterations. Traditional reductionist approaches are often insufficient to capture this complexity. In contrast, omics-based technologies enable comprehensive, unbiased profiling of tumors and their microenvironment, offering unprecedented insights into oncogenic pathways, immune modulation, tumor evolution and inter-patient variability.

Recent advances in multi-omics integration, single-cell sequencing, spatial omics and artificial intelligence–driven data analysis are further accelerating discoveries in cancer research and clinical oncology. These developments are redefining biomarker discovery, patient stratification, drug development and personalized medicine.

This Special Issue aims to gather high-quality original research articles and authoritative reviews that highlight the application of omics approaches in cancer research, from fundamental molecular mechanisms to translational and clinical perspectives.

By focusing on molecular signatures, regulatory networks and integrative omics analyses, this Special Issue seeks to foster interdisciplinary dialog between molecular biologists, bioinformaticians and translational researchers.

In this Special Issue, original research articles, reviews and systematic reviews are welcome. Research areas may include, but are not limited to, the following topics:

  • Cancer genomics
  • Cancer epigenomics
  • Transcriptomics and non-coding RNA profiling in cancer
  • Proteomics in tumor signaling
  • Cancer metabolomics
  • Tumor microbiome
  • Single-cell and spatial omics in tumor heterogeneity
  • Multi-omics data integration and systems biology approaches
  • Omics-driven biomarker discovery for diagnosis and prognosis
  • Omics approaches to cancer immunology and immunotherapy
  • Precision oncology, drug resistance and treatment response prediction

We look forward to receiving your valuable contributions to this Special Issue.

Prof. Dr. Hassan Ghazal
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • omics
  • genomics
  • transcriptomics
  • proteomics
  • metabolomics
  • multi-omics
  • biomarkers
  • precision oncology
  • systems biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

24 pages, 1399 KB  
Article
Metabolic and Clinical–Nutritional Correlation Patterns in Relation to 3-Year Disease-Free Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Preliminary Analysis
by Łukasz Boguszewicz, Agata Hajduk-Bieleń, Mateusz Ciszek, Agnieszka Skorupa, Jolanta Mrochem-Kwarciak, Krzysztof Składowski and Maria Sokół
Int. J. Mol. Sci. 2026, 27(15), 6715; https://doi.org/10.3390/ijms27156715 - 27 Jul 2026
Viewed by 341
Abstract
This retrospective study characterizes the complex associations between serum 1H-NMR metabolomics, clinical nutritional status, and laboratory blood parameters in men with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in relation to 3-year disease-free survival (DFS). A total of 536 serum samples [...] Read more.
This retrospective study characterizes the complex associations between serum 1H-NMR metabolomics, clinical nutritional status, and laboratory blood parameters in men with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in relation to 3-year disease-free survival (DFS). A total of 536 serum samples from 67 patients, collected weekly during radiotherapy or chemoradiotherapy, were analyzed to characterize the metabolic-nutritional landscape. The patients with 3-year DFS exhibited stronger biological links between elevated levels of serum lipids, phosphocholine, branched-chain amino acids (BCAAs), and clinical markers such as BMI, albumin, and prealbumin compared to those with disease recurrence. Furthermore, our findings highlight a novel pattern of disrupted correlations (metabolic decoupling) between body fat distribution, overall obesity, and lipid metabolism, as well as the links between BCAAs and nutritional status, in patients with disease recurrence. This observed breakdown of internal coordination suggests that the survival advantage associated with body fat arises not just from adiposity, but from the body’s ability to metabolically coordinate fat and amino acid turnover with overall energy demands—a trait known as metabolic flexibility. In conclusion, we hypothesize that disease recurrence in men with LA-HNSCC is driven by failure of this system, manifested as a breakdown in the coordination between metabolic and nutritional profiles. The preserved metabolic-nutritional axis between fat turnover and nutrient availability is associated with 3-year disease-free survival in this patient group, although more research is required to fully elucidate the underlying mechanisms. Full article
(This article belongs to the Special Issue Recent Advances in Omics for Cancer Research)
►▼ Show Figures

Figure 1

18 pages, 4382 KB  
Article
Artificial Intelligence-Enabled Analysis of WNT Pathway Dysregulation in Bevacizumab-Treated Early-Onset Colorectal Cancer
by Erika Ruiz-Garcia, Brigette Waldrup, Francisco G. Carranza, Sophia Manjarrez, Edith A. Fernandez-Figueroa and Enrique Velazquez-Villarreal
Int. J. Mol. Sci. 2026, 27(14), 6195; https://doi.org/10.3390/ijms27146195 - 11 Jul 2026
Viewed by 498
Abstract
Early-onset colorectal cancer (EOCRC) is increasing disproportionately among Hispanic/Latino (H/L) populations and demonstrates substantial molecular and clinical heterogeneity. Although Wingless/Integrated (WNT) pathway alterations are among the most common genomic events in colorectal cancer, their prognostic significance in the context of contemporary systemic therapies, [...] Read more.
Early-onset colorectal cancer (EOCRC) is increasing disproportionately among Hispanic/Latino (H/L) populations and demonstrates substantial molecular and clinical heterogeneity. Although Wingless/Integrated (WNT) pathway alterations are among the most common genomic events in colorectal cancer, their prognostic significance in the context of contemporary systemic therapies, including Bevacizumab, remains incompletely understood. We conducted an integrative clinical–genomic analysis of colorectal cancer cohorts stratified by age at diagnosis, ancestry, and Bevacizumab exposure, interrogating somatic alterations across curated WNT signaling pathway genes. Conversational artificial intelligence agents (AI-HOPE and AI-HOPE-WNT) enabled dynamic cohort construction, treatment-specific subgroup analyses, and pathway-level interrogation through natural language-driven clinical–genomic integration. WNT pathway alterations, predominantly involving APC, were highly prevalent across all cohorts; however, their distribution and clinical associations demonstrated strong treatment-, ancestry-, and age-dependent variability. Bevacizumab-treated tumors exhibited lower mutation frequencies in several WNT regulators, including RNF43, AXIN1/2, TCF7L2, and AMER1, suggesting potential biologic interaction or treatment-related selective pressure. Importantly, WNT pathway alterations were associated with improved overall survival in H/L EOCRC and Non-Hispanic White (NHW) late-onset colorectal cancer, but with worse survival in NHW EOCRC, highlighting distinct ancestry- and age-specific prognostic effects. These findings support the role of the WNT pathway dysregulation as a disparity-aware biomarker framework in colorectal cancer and demonstrate the utility of conversational AI systems for scalable multidimensional clinical–genomic integration in precision oncology. Full article
(This article belongs to the Special Issue Recent Advances in Omics for Cancer Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop